Pimasertib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Pimasertib
Accession Number
DB14904
Type
Small Molecule
Groups
Investigational
Description

Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
6ON9RK82AL
CAS number
1236699-92-5
Weight
Average: 431.206
Monoisotopic: 431.01421
Chemical Formula
C15H15FIN3O3
InChI Key
VIUAUNHCRHHYNE-JTQLQIEISA-N
InChI
InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
IUPAC Name
N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide
SMILES
OC[C@@H](O)CNC(=O)C1=C(NC2=C(F)C=C(I)C=C2)C=NC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
24747378
BindingDB
50014412
ChEBI
94793
ChEMBL
CHEMBL2107832

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBreast Cancer / Colorectal Cancers / Locally Advanced Solid Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Metastatic Solid Tumors1
1CompletedTreatmentLocally Advanced or Metastatic Solid Tumors1
1CompletedTreatmentMalignancies / Tumors, Solid1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms Malignant1
1TerminatedTreatmentAdvanced Solid Tumors1
1TerminatedTreatmentAdvanced Solid Tumors / Hepatocellular,Carcinoma1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas1
1, 2TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
2CompletedTreatmentN-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma1
2CompletedTreatmentOvarian Cancer1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Neoplasms, Hematologic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0986 mg/mLALOGPS
logP1.17ALOGPS
logP2.32ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)13.76ChemAxon
pKa (Strongest Basic)3.72ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area94.48 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity92.2 m3·mol-1ChemAxon
Polarizability36.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:33 / Updated on February 02, 2020 03:17